Interestingly, recent studies demonstrate that co-administration of L-DOPA with a neuroprotective agent that inhibits excitotoxicity, oxidative stress, and neuroinflammation reduces LID in animal models of PD (Spinnewyn et al., 2011; Aron Badin et al., 2013).